These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 6638984

  • 21. Role of individual drugs in the chemotherapy of tuberculosis.
    Mitchison DA.
    Int J Tuberc Lung Dis; 2000 Sep; 4(9):796-806. PubMed ID: 10985648
    [Abstract] [Full Text] [Related]

  • 22. [A case of pulmonary tuberculosis with acute renal failure caused by readministration of rifampicin].
    Kuroda F, Yagi T, Yamagishi F, Mizutani F, Sasaki Y, Wada A.
    Kekkaku; 1999 Nov; 74(11):803-7. PubMed ID: 10599213
    [Abstract] [Full Text] [Related]

  • 23. [Efficacy of different methods of treating experimental cavernous tuberculosis of a single kidney].
    Mazaev MB.
    Probl Tuberk; 1984 Feb; (2):67-9. PubMed ID: 6709627
    [No Abstract] [Full Text] [Related]

  • 24. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
    Schall R, Müller FO, Duursema L, Groenewoud G, Hundt HK, Middle MV, Mogilnicka EM, Swart KJ.
    Arzneimittelforschung; 1995 Nov; 45(11):1236-9. PubMed ID: 8929247
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, Pou L, Sánchez P, Sambeat MA, Colomer J, Lopez-Colomes JL, Crespo M, Falcó V, Ocaña I, Pahissa A.
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [Abstract] [Full Text] [Related]

  • 26. Drug interactions -- the influence of rifampicin and clofazimine on the urinary excretion of DDS.
    Balakrishnan, Seshadri PS.
    Lepr India; 1981 Jan; 53(1):17-22. PubMed ID: 7218762
    [Abstract] [Full Text] [Related]

  • 27. Serum concentrations of rifampicin and isoniazid in tuberculosis.
    Seth V, Beotra A, Seth SD, Semwal OP, Kabra S, Jain Y, Mukhopadhya S.
    Indian Pediatr; 1993 Sep; 30(9):1091-8. PubMed ID: 8125594
    [Abstract] [Full Text] [Related]

  • 28. Disposition of uric acid upon administration of ofloxacin alone and in combination with other anti-tuberculosis drugs.
    Kumar AK, Gurumurthy P.
    Indian J Exp Biol; 2004 Mar; 42(3):323-5. PubMed ID: 15233305
    [Abstract] [Full Text] [Related]

  • 29. Pyrazinamide serum levels in childhood tuberculosis.
    Thee S, Detjen A, Wahn U, Magdorf K.
    Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511
    [Abstract] [Full Text] [Related]

  • 30. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
    Ahn HC, Lee YC.
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
    [Abstract] [Full Text] [Related]

  • 31. [Tuberculostatic activity of the blood and urinary excretion of tubazid in patients with renal tuberculosis].
    Savula MM, Khoma-Lemishko AM.
    Probl Tuberk; 1971 Jun; 49(8):61-4. PubMed ID: 5152636
    [No Abstract] [Full Text] [Related]

  • 32. Long-term renoprotective effect of combination therapy with prostaglandin E1 and angiotensin-converting enzyme inhibitor in patients with chronic renal failure.
    Nakayama Y, Nonoguchi H, Kiyama S, Kohda Y, Inoue T, Tomita K.
    Hypertens Res; 2005 Sep; 28(9):733-9. PubMed ID: 16419646
    [Abstract] [Full Text] [Related]

  • 33. [The dobutamine-dopamine combination versus amrinone in congestive heart failure with a marked edematogenic sign complicated by functional kidney failure. A comparison between 2 different models of inotropic stimulation and diuresis potentiation].
    De Vecchis R, Pucciarelli G, Nocerino L, Cocozza M, Setaro A, Torre G, Imperatore F.
    Minerva Cardioangiol; 1998 May; 46(5):163-74. PubMed ID: 9842199
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
    Roy V, Tekur U, Chopra K.
    Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
    [Abstract] [Full Text] [Related]

  • 35. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India.
    Shah AR, Agarwal SK, Shah KV.
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1098-101. PubMed ID: 12546118
    [Abstract] [Full Text] [Related]

  • 36. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z, Augustynowicz-Kopeć E, Niemirowska-Mikulska H.
    Acta Pol Pharm; 2002 Dec; 59(6):448-52. PubMed ID: 12669769
    [Abstract] [Full Text] [Related]

  • 37. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
    Pandey R, Sharma S, Khuller GK.
    Tuberculosis (Edinb); 2005 Dec; 85(5-6):415-20. PubMed ID: 16256437
    [Abstract] [Full Text] [Related]

  • 38. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG, Chernousova LN, Andreevskaia SN, Nikolaeva GM.
    Probl Tuberk Bolezn Legk; 2004 Dec; (3):32-7. PubMed ID: 15338898
    [Abstract] [Full Text] [Related]

  • 39. Study on drug interactions.
    Venkatesan K, Bharadwaj VP, Ramu G, Desikan KV.
    Lepr India; 1980 Apr; 52(2):229-35. PubMed ID: 7453137
    [Abstract] [Full Text] [Related]

  • 40. [Rifampicin levels in blood, urine and kidney tissue in patients with renal tuberculosis].
    Mochalova TP, Kanevskaia SS, Danilova NK.
    Antibiotiki; 1973 Feb; 18(2):178-80. PubMed ID: 4776397
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.